Telix Files BLA for TLX250-CDx (Zircaix®) in Kidney Cancer Imaging, Setting the Stage for a Breakthrough in Diagnosis
Generated by AI AgentMarcus Lee
Sunday, Dec 29, 2024 5:07 pm ET1min read
TLX--
Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent, TLX250-CDx (Zircaix™, 89Zr-DFO-girentuximab), for the imaging of clear cell renal cell carcinoma (ccRCC). This submission marks a significant milestone for Telix, as it paves the way for the commercial availability of this novel, non-invasive imaging agent for kidney cancer patients in the U.S. in 2024, subject to regulatory review and approval.
Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent, TLX250-CDx (Zircaix™, 89Zr-DFO-girentuximab), for the imaging of clear cell renal cell carcinoma (ccRCC). This submission marks a significant milestone for Telix, as it paves the way for the commercial availability of this novel, non-invasive imaging agent for kidney cancer patients in the U.S. in 2024, subject to regulatory review and approval.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet